-
1 Comment
CABIO Biotech(Wuhan) Co., Ltd is currently in a long term uptrend where the price is trading 7.6% above its 200 day moving average.
From a valuation standpoint, the stock is 19.2% more expensive than other stocks from the None sector with a price to sales ratio of 14.8.
CABIO Biotech(Wuhan) Co., Ltd's total revenue rose by 8.5% to $87M since the same quarter in the previous year.
Its net income has dropped by 7.6% to $20M since the same quarter in the previous year.
Finally, its free cash flow fell by 21.3% to $42M since the same quarter in the previous year.
Based on the above factors, CABIO Biotech(Wuhan) Co., Ltd gets an overall score of 2/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| Sector | Healthcare |
| Industry | Biotechnology |
| ISIN | CNE100005X31 |
| PE Ratio | 28.76 |
|---|---|
| Target Price | 17 |
| Beta | 0.55 |
| Market Cap | 4B |
| Dividend Yield | None |
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. Its products are used in infant formula food, health food, dietary supplements, and other fields for special medical purposes, pet nutrition food, economic animal feed, personal care and cosmetics, and other fields. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 688089.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
